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Abstract
Purpose of Review Critical appraisal of the available evidence on the self-expanding ACURATE neo transcatheter heart valve
(THV) for the treatment of aortic valve disease.
Recent Findings In an investigator-initiated, multicenter, randomized non-inferiority trial with broad inclusion criteria,
ACURATE neo failed to meet non-inferiority compared with SAPIEN 3 with regard to a primary composite safety and efficacy
endpoint at 30 days. The difference was driven by higher rates of moderate or severe paravalvular regurgitation and higher rates
of acute kidney injury. In turn, registry data suggest that the safety and efficacy profile of the ACURATE neo is comparable to
that of other commercially available devices. Randomized evidence indicated favorable hemodynamic results with large effective
orifice areas and low residual gradients.
Summary The self-expanding ACURATE neo THV is associated with higher rates of residual aortic regurgitation compared to
the balloon-expandable SAPIEN 3 THV. The supra-annular design with low residual gradients may be advantageous in patients
with small anatomy and mild degree of calcification.
Keywords Transcatheter aortic valve replacement, ACURATE neo . Self-expanding . Balloon-expandable . Transcatheter heart
valve . SCOPE
Introduction
Since the introduction of transcatheter aortic valve replace-
ment (TAVR) as an alternative for inoperable patients with
severe aortic stenosis [1], advances in treatment strategies and
refinement of valve systems have expedited the expansion of
TAVR to surgical low-risk patients [2, 3]. Nowadays, TAVR
is considered a valuable treatment strategy across the entire
spectrum of surgical risk based on robust evidence derived
from iterative randomized clinical trials and large-scale real-
world registries [4]. Strategy trials comparing TAVR to sur-
gical aortic valve replacement (SAVR) have been performed
with different generations of transcatheter heart valve (THV)
systems of the balloon-expandable SAPIEN series (Edwards
Lifesciences, Irvine, CA, USA) and the self-expanding
CoreValve/Evolut series (Medtronic, Minneapolis, MN,
USA). A number of novel THVs have been introduced with
the aim to overcome limitations of these two dominant market
players [5••, 6–9]. Among them, the ACURATE neo THV
(Boston Scientific, Marlborough, MA, USA) is one of the
leading devices, which has a unique valve design and deploy-
ment mechanism [5••]. In this review, we summarize the
available evidence on this device and elucidate its strengths
and weaknesses as compared to other commercially available
THV devices.
The ACURATE neo: Device Characteristics
and Deployment Mechanism
The ACURATE neo is composed of porcine pericardial leaf-
lets mounted on a self-expanding nitinol stent frame in supra-
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annular position and is implanted in a top-down two-step re-
lease mechanism. This unique deployment mechanism mini-
mizes peri-procedural outflow obstruction and allows for sta-
ble positioning without rapid ventricular stimulation. Three
stabilization arches and the protruding upper crown further
enhance co-axial deployment and device stabilization
(Fig. 1). In addition, the upper crown may deter the native
leaflets from the coronary ostia and reduce the risk of coronary
obstruction (Fig. 1). Currently, three sizes of the THV (S, M,
L) are available and accommodate aortic annular diameters
ranging from 21 to 27 mm. The delivery system is compatible
with an 18-Fr (15-Fr expandable) sheath. Pre-dilatation is re-
quired prior to valve implantation according to the instructions
for use in order to allow adequate device expansion.
The ACURATE neo Device for Native Aortic
Valve Stenosis
Several studies have investigated the clinical outcomes up to
1 year after implantation of the ACURATE neo THV for
treatment of severe aortic stenosis in elderly patients
(Table 1) [10–12, 13•, 14•, 15, 16, 17•, 18•, 19, 20]. These
studies have proposed some strengths and drawbacks of
ACURATE neo, which may guide how to optimally tailor
the device to the most appropriate anatomy.
The top-down two-step deployment mechanism with
stabilization arches and an upper crown anchoring the
device in the aortic annulus facilitates stable deployment
and mitigates the risk of device migration and potentially
also coronary obstruction (Fig. 1). Malpositioning oc-
curred in 0.5 to 2.2% across studies conducted in patients
treated for severe stenosis of the native aortic valve [10,
11, 15]. The incidence of coronary obstruction was negli-
gible when the ACURATE neo device was implanted in
native tricuspid aortic valves [10, 11, 13•, 15]. The nitinol
frame of the ACURATE neo THV has a lower radial
force as compared to other self-expanding THVs (Fig.
1), thus requiring pre-dilatation and increasing the need
for post-dilatation [5••]. The lower radial force may lead
to less mechanical injury to the conduction system (Fig.
1) and explain the relatively low need for a new perma-
nent pacemaker ranging from 8.3 to 12.3% [10–12, 13•,
15, 16, 17•], which is considerably lower than reported
pacemaker rates of other self-expanding THVs (17.4 to
34.1%) [3, 21]. Evidence from a small multicenter study
suggested that the rate of new permanent pacemakers can
be reduced to 2.3% when applying a minimizing trauma
strategy using a smaller balloon for pre- and post-dilation
[12]. On the downside, the lower radial force may trans-
late into malappositioning of the device to the aortic an-
nulus and increase the risk of paravalvular regurgitation
despite the presence of an outer skirt (Fig. 1). In a ran-
domized trial among 739 patients from 20 centers, the
occurrence of valve-related dysfunction, mainly moderate
or severe aortic regurgitation, at 30 days, was significant-
ly higher among patients treated with ACURATE neo
( 9%) compa r e d t o Edwa r d s SAP IEN 3 ( 3%)
(P < 0.0001) [5••]. In contrast, site-reported incidence of
relevant paravalvular regurgitation (moderate to severe) in
observational studies was considerably lower, ranging
from 1.4 to 4.8% [10–12, 13•, 14•, 15, 16]. The supra-
annular design of the THV achieves a larger effective
orifice area (EOA) with lower transprosthetic gradients,
and potentially prevents prosthesis-patient mismatch
(Fig. 1) [22]. Across the studies, EOA and mean
transprosthetic gradients ranged from 1.6 to 2.0 cm2 and
from 6.9 to 10.6 mmHg (mean or median), respectively
[10–12, 13•, 14•, 15, 16, 17•]. In a propensity-score-
matched comparison in patients with a small aortic annu-
lus (area < 400 mm2), the ACURATE neo THV was asso-
ciated with a significantly lower incidence of prosthesis-
patient mismatch as compared with the SAPIEN 3 THV
[23]. Finally, 30-day mortality was reported as 0.6 to
3.4%, which were comparable to the results of TAVR
randomized clinical trials [10–12, 13•, 14•, 15, 16, 17•].
Fig. 1 Unique design of the
ACURATE neo transcatheter
heart valve. Overview of the
unique features of the device and
their clinical relevance are
presented. (Image/content
provided courtesy of Boston
Scientific. © 2020 Boston
Scientific Corporation or its
affiliates. All rights reserved)
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The ACURATE neo for Bicuspid Aortic Valve
Bicuspid anatomy was an exclusion criterion in the random-
ized SCOPE trial, and evidence on ACURATE neo in patients
with bicuspid aortic stenosis is limited to a modestly sized
case series. The performance of the ACURATE neo THV in
bicuspid aortic stenosis was investigated in an international
registry including 54 patients with a bicuspid aortic valve
and 658 patients with a tricuspid aortic valve (Table 1)
[17•]. Coronary occlusion occurred in one patient with a bi-
cuspid valve (1.8%). After propensity score matching, a sim-
ilar hemodynamic performance (9.8 ± 4.2 mmHg vs. 9.9 ±
4.5 mmHg, P = 0.944) and a comparable rate of relevant
paravalvular regurgitation (7.4% vs. 5.5%, P = 0.734) were
observed. However, the rate was significantly higher than that
of unmatched tricuspid valve patients (7.4% vs. 3.1%, P =
0.0001), suggesting a substantially increased risk of
paravalvular regurgitation. Thus, considering the rather low
radial force of the ACURATE neo THV, it may not be an
optimal device for often heavily calcified bicuspid aortic
valves.
The ACURATE neo for Degenerated Surgical
Aortic Bioprostheses
The international experience of 85 patients using the
ACURATE neo THV for the treatment of degenerated surgi-
cal aortic bioprostheses was reported from 14 centers in
Europe and Canada (Table 1) [18•]. Malpositioning of the
device was reported in two (2.4%) patients and coronary ob-
struction in one (1.2%) patient. Overall, an acceptable hemo-
dynamic performance with an EOA of 1.5 ± 0.4 cm2 a mean
gradient of 16 ± 8 mmHg was achieved despite the predomi-
nance of small-size (S) THVs. This study elucidated an im-
portant consideration for valve-in-valve procedures using the
ACURATE neo THV. Since the upper crown is protruding
5 mm from the waist of the stent body, the crown may inter-
fere with the stent posts and leaflets of the degenerated surgi-
cal aortic bioprosthesis, which may result in incomplete ex-
pansion, if the upper crown is positioned inside the
bioprosthesis. In the study, a high implantation of the THV
with the upper crown above the degenerated bioprosthesis was
associated with significantly better hemodynamic outcomes
(mean gradients: 14 ± 6 mmHg vs. 19 ± 10 mmHg, P =
0.001; EOA: 1.56 ± 0.37 cm2 vs. 1.36 ± 0.34 cm2, P =
0.045), but had increased risks of valve migration and early
valve deterioration as compared with a low implantation.
Further study is needed to clarify the short-term and long-
term performance of this unique THV in the setting of
valve-in-valve procedures for degenerated surgical aortic
bioprostheses.T
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The ACURATE neo THV for Native Pure Aortic
Valve Regurgitation
TAVR is an alternative to SAVR for inoperable patients with
aortic regurgitation. The off-label use of the ACURATE neo
THV in patients with native pure aortic regurgitation is limited
to small case series [19, 20]. Native pure aortic regurgitation is
frequently characterized by the absence of annular and leaflet
calcification, which complicates THV anchoring and in-
creases the risk of device migration. The increased stroke vol-
ume secondary to aortic regurgitation and the presence of
aortic root dilation render accurate device positioning difficult
and may further increase the risk of device migration [24]. In
this context, the ACURATE neo THV may have notable ad-
vantages owing to its unique x-shaped design and the deploy-
ment system (Fig. 1). In the absence of calcification, the pro-
truding upper crown may serve as a safety anchor to prevent
its dislocation into the left ventricular outflow tract (LVOT).
Furthermore, the stable top-down two-step deployment sys-
tem may be less affected by the increased stroke volume and
facilitate the accurate positioning of the THV. Currently, two
small multicenter experiences of the ACURATE neo THV for
native pure aortic regurgitation have been published (Table 1)
[19, 20]. In the first series of 20 patients, rapid pacing was
used during THV implantation in 70% of the patients [19]. In
one case (5%), a second THV implantation was required due
to a low positioning of the initial THV. In contrast, in the
second series of 24 cases, rapid pacing was used in 20% of
cases only, and a second THV implantation was required in
three cases (12.5%), in one case for severe paravalvular regur-
gitation (4.1%), and in two cases for device migration (8.3%)
[20]. In the two case series, relevant paravalvular regurgitation
was observed in one (5%) and two (8.3%) patients, respec-
tively [19, 20]. Mean THV oversizing was close to 10% and
resulted in new pacemaker implantation rates of 15% and
21%, respectively [19, 20]. In summary, transfemoral TAVR
with the ACURATE neo THV may be an option for the treat-
ment of pure aortic regurgitation in selected inoperable pa-
tients with suitable anatomy.
Comparison with Other Contemporary
Devices
Balloon-expandable THVs from the SAPIEN family and self-
expanding THVs from the CoreValve/Evolut family have
been extensively tested in randomized clinical trials and rep-
resent the benchmark for new devices [4]. The ACURATE
neo THV has been compared to the balloon-expanding
Edwards SAPIEN 3 THV in one randomized controlled trial
and six propensity-score-matched studies [5•, 23–30]
(Table 2).
The SCOPE I trial was a randomized non-inferiority
trial comparing ACURATE neo versus SAPIEN 3 in 739
patients with severe aortic stenosis with regard to a primary
composite safety and efficacy endpoint at 30 days. TAVR
with ACURATE neo failed to meet non-inferiority com-
pared to SAPIEN 3 with respect to the composite of all-
cause death, any stroke, life-threatening or disabling bleed-
ing, major vascular complications, coronary artery obstruc-
tion, acute kidney injury (stage 2 or 3), rehospitalization
for valve-related symptoms or congestive heart failure,
valve-related dysfunction requiring repeat procedure, mod-
erate or severe prosthetic valve regurgitation, or prosthetic
valve stenosis within 30 days of the procedure [5••]. The
difference was largely driven by a higher rate of moderate
or severe paravalvular regurgitation in patients treated with
ACURATE neo compared to SAPIEN 3 (9% vs. 3%,
P < 0.0001). In turn, the transvalvular gradient was lower
and the mean effective orifice area larger in patients treated
with ACURATE neo compared with SAPIEN 3.
A low incidence of atrioventricular conductance distur-
bances requiring permanent pacemaker implantation com-
pared not only to self-expanding but also to balloon-
expandable devices has been considered an important
strength of the unique design of the ACURATE neo THV.
While retrospective cohort studies have shown a significant-
ly lower rate of permanent pacemaker implantation in pa-
tients treated with ACURATE neo compared with SAPIEN
3 [24, 26, 27], findings from the SCOPE I trial indicate com-
parable rates of permanent pacemaker implantation (10%vs.
9%,P = 0.76) [5••]. Interestingly, amulticenter study includ-
ing only patients with pre-existing right bundle branch block
demonstrated a significantly lower incidence of new pace-
maker implantation in theACURATEneoTHVas compared
to the SAPIEN 3 THV (23.1% vs. 44.6%, P = 0.016) [26].
The SCOPE I trial also suggested an increased risk of acute
kidney injury following TAVR in the ACURATE neo THV,
which may be attributable to increased contrast volume as-
sociatedwith the longerprocedural timedue tomore frequent
pre- and post-dilation [5••]. Although the difference was not
observed in other retrospective studies, rates of pre- andpost-
dilationwere consistently higher in theACURATEneoTHV
[23–27], and some studies showed larger contrast volume
and longer procedural time as compared to the SAPIEN 3
THV [25, 28].
A randomized clinical trial comparing the ACURATE neo
THV versus the Evolut R/PRO THV has recently completed
patient enrollment, and the results will soon be available
(NCT03192813). A propensity-score-matched comparison
suggested comparable short-term outcomes, including device
success, relevant paravalvular regurgitation, all-cause death,
stroke, new permanent pacemaker, and early safety endpoint,
between the two self-expanding THVs (Table 2) [29•]. Data
on long-term valve durability is missing at this stage.
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Place for the ACURATE neo THV
The ACURATE neo THV may not be the optimal device for
patients with excessive leaflet calcification and LVOT calci-
fication, in which an increased risk of paravalvular regurgita-
tion following TAVR is anticipated [31–34]. However, some
specific patient groups may benefit from the unique design of
the ACURATE neo THV.
Patients at High Risk of Conduction Disturbances
A low risk of permanent pacemaker implantation com-
pared with other self-expanding devices makes
ACURATE neo a valuable device in patients with pre-
existing conduction disturbances, i.e., right bundle
branch block, and may facilitate early discharge follow-
ing TAVR [27, 35].
Table 2 Results of comparison studies of ACURATE neo with SAPIEN 3 and Evolut R/PRO
Study design
Author (year)
Baseline of ACURATE-arm Valve performance Clinical outcome
N Age Surgical score Hemodynamic results PVL Pacemaker
implantation
AKI stage 2 or 3 30-day
mortality
Versus SAPIEN 3
PS-matched
comparison
Husser et al. (2017)
[25]
311 81 ± 6 LES: 18 ± 10% 9 ± 5 vs. 13 ± 5 mmHg
(P < 0.001)
4.8% vs. 1.8%
(P = 0.008)
10.2% vs. 16.4%
(P = 0.018)
3.2% vs. 2.7%
(P = 0.679)
2.3% vs.
1.9%
(P = 0.742)
PS-matched
comparison*1
Mauri et al. (2017)
[23]
92 83 ± 7 LES:
16.2 ± 8.8%
9.3 ± 3.9 vs. 14.5 ± 5.5 mmHg
(P < 0.001)
4.5% vs. 3.6%
(P = 0.208)
12.0% vs. 15.2%
(P = 0.678)
NA 1.1% vs.
2.2%
(P = 1.000)
PS-matched
comparison
Schaefer et al.
(2017)
[26]
104 82 ± 6 LES:
15.9 ± 9.3%
STS:
5.8 ± 3.8%
7.3 ± 2.8 vs. 11.8 ± 3.5 mmHg
(P < 0.001)
4.8% vs. 1.9%
(P = 0.257)
10.6% vs. 16.4%
(P = 0.239)
2.9% vs. 1.9%
(P = 0.655)
3.9% vs.
0.9%
(P = 0.317)
PS-matched
comparison*2
Husser et al. (2019)
[27]
65 81
(77–84)
LES: 14.3%
(9.8–21.5)
7(5–10) vs. 11(9–12, 13•, 14•)
mmHg
(P < 0.001)
4.6% vs. 0%
(P = 0.244)
23.1% vs. 44.6%
(P = 0.016)
1.5% vs. 7.7%
(P = 0.208)
3.1% vs.
6.2%
(P = 0.680)
PS-matched
comparison
Barth et al. (2019)
[28]
329 81 ± 5 LES:
18.8 ± 14.7%
8.6 ± 4.6 vs. 10.9 ± 4.2 mmHg
(P < 0.001)
12.0% vs.
3.1%
(P < 0.001)
11.9% vs. 18.5%
(P = 0.020)
NA 4.6% vs.
2.1%
(P = 0.134)
Randomized
clinical trial+
Lanz et al. (2019)
[5••]
372 83 ± 4 STS: 3.7%
(2.5–4.9)
7(1–15) vs. 11(2–23) mmHg
(P < 0.0001)
9.4% vs. 2.8%
(P < 0.0001)
10% vs. 9%
(P = 0.76)
3% vs. 1%
(P = 0.0340)
2% vs. 1%
(P = 0.09)
Versus Evolut PRO
PS-matched
comparison
Pagnesi et al.
(2019)
[29•]
251 81 ± 7 ES II:
6.34 ± 5.21%
STS:
5.08 ± 3.05%
8.3 ± 4.0 vs. 7.3 ± 3.6 mmHg
(P = 0.003)
7.3% vs. 5.7%
(P = 0.584)
11.0% vs. 12.8%
(P = 0.565)
2.4% vs. 1.6%
(P = 0.543)
3.2% vs.
1.2%
(P = 0.221)
Versus SAPIEN 3 versus Evolut R
PS-matched
comparison
Costa et al. (2020)
[30]
48 82
(80–-
85)
STS: 4.0 ± 3.3% 8.4 ± 3.5 vs. 9.7 ± 7.5 vs.
6.1 ± 2.4 mmHg
(P < 0.001)
0% vs. 0% vs.
2.1%
(P < 0.01)
2.1% vs. 8.3% vs.
16.7%
(P = 0.046)
1.0% vs. 2.2%
vs. 2.7%
(P = 0.659)
0% vs. 0%
vs. 0%
(P =NA)
PS propensity score,PVL paravalvular leak,ES IIEuroscore II, LES logistic Euroscore, STS Society of Thoracic Surgeons predicted risk of mortality,NA
not available/assessed
+ Independent event adjudication and echocardiographic core laboratory assessment were applied (no other studies comprised independent event
adjudication or core laboratory echocardiographic assessment)
*1 Selective cohort with an aortic annulus area < 400 mm2
*2 Selective cohort with pre-existent right bundle branch block and no pacemaker at baseline
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Patients at High Risk of Coronary Obstruction or
Future Coronary Re-access
Conceptually, the THV may mitigate the risk of coronary
obstruction in patients with low coronary distance, small sinus
of Valsalva, and long leaflets [36, 37]. Furthermore, coronary
re-access may be less challenging as compared to the other
THVs because of the short stent body and the open-cell design
of the upper crown. Patients with coronary artery disease at
risk of future percutaneous coronary interventions may be
suitable candidates for this THV [38–40].
Patients at High Risk of Prosthesis-Patient Mismatch
The ACURATE neo valve may be useful in patients with a
small anatomy that my benefit from the supra-annular design
to reduce the risk of prosthesis-patient mismatch [22].
Patients with Horizontal Aorta
Increased aortic root angulation has been shown to adversely
influence acute procedural success following other self-
expanding THV (CoreValve) possibly due to its long stent
frame and less flexible delivery system [41]. Therefore, the
short stent frame and the flexible delivery system of the
ACURATE neo may be advantageous in these situations.
The unique stabilization arches may also provide a better co-
axial alignment and facilitate accurate deployment.
Conclusions
The ACURATE neo THV conceptually differs from other
self-expanding valves with a two-step top-down release mech-
anism. Low radial strength reduces the need for permanent
pacemaker implantation and comes at the expense of an in-
creased risk of paravalvular aortic regurgitation compared to
the SAPIEN 3 THV. Data on long-term outcomes and valve
durability is missing.
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